Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

BOTHELL, WA, and VANCOUVER, May 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced preliminary results of a Phase 1 trial presented during an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. Preliminary results as of April 2009 showed that OGX-427 was well tolerated as a monotherapy. In addition, OGX-427 demonstrated declines in circulating tumor cells at all doses evaluated as well as evidence of reduction in tumor markers. Reductions in circulating tumor cells and tumor markers both suggest single-agent activity warranting further clinical investigation.

The Phase 1 trial has evaluated 41 patients with a variety of cancers to date; enrollment is ongoing. The first phase of the study evaluated increasing doses of OGX-427 as a single agent up to 1000 mg. A maximum tolerated dose was not identified up to and including the 1000-mg dose of OGX-427 monotherapy. Subsequently, as defined by the protocol, an 800-mg dose of OGX-427 in combination with docetaxel was evaluated, to be followed by a 1000-mg dose of OGX-427 plus docetaxel. OGX-427 is administered as three loading doses within the first 9 days and then continued weekly, with three weeks defined as a treatment cycle, until disease progression or toxicity. In those groups receiving OGX-427 in combination with docetaxel, 75mg/M(2) docetaxel was administered on Day 1 of every 3-week cycle starting after completion of the OGX-427 loading doses.

Safety Results

Patients enrolled had a diagnosis of breast, ovarian, prostate or non-small cell lung cancer and most had failed multiple prior chemotherapy treatments. A median of 2 cycles (range of 1-8 cycles) was administered with the following safety results for OGX-427 as monotherapy:

    -   Criteria for a maximum tolerated dose were 
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... San Diego, CA (PRWEB) January 14, 2014 ... based on the products of cells grown under simulated ... an international license agreement with Suneva Medical, Inc. for ... media (CCM). , This agreement is an ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 As pet owners drew ... doubt many of them wrote: "Take better care of my furry ... even designer clothes and top-brand carrying cases to take the little ... parents might also feel compelled to buy some pricey toys at ...
(Date:1/14/2014)... Texas , Jan. 14, 2014 The ... and research medicinal plants and therapeutic derivatives thereof ... health professionals, and researchers about the challenges of ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society ...
(Date:1/14/2014)... MA (PRWEB) January 14, 2014 iLab Solutions, ... Detwiler as the new Director of Product Strategy. In this ... well as iLab sub-teams to guide in the development of ... iLab provides the maximum possible benefit to the scientific community ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... Bioscience Appoints Two Industry Executives to Realigned Advisory Board -- VIENNA, Austria, September 2, 2010 ... ... lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
... Institute of Standards and Technology (NIST) have demonstrated a ... for a wide variety of fields dealing with things ... a few nanoliters. Currently a table-top prototype, the NIST ... studying minute quantities of complex materials that must function ...
... (Nasdaq: MATK ) today announced its financial results ... third quarter were $117.2 million, up 51% from $77.8 million ... was $11.9 million, or $0.35 per diluted share, for the ... to $8.9 million, or $0.27 per diluted share, for the ...
Cached Biology Technology:EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board 2EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board 3EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board 4EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board 5EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board 6EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board 7Micro rheometer is latest Lab On a Chip device 2Martek Announces Third Quarter FY 2010 Financial Results 2Martek Announces Third Quarter FY 2010 Financial Results 3Martek Announces Third Quarter FY 2010 Financial Results 4Martek Announces Third Quarter FY 2010 Financial Results 5Martek Announces Third Quarter FY 2010 Financial Results 6Martek Announces Third Quarter FY 2010 Financial Results 7Martek Announces Third Quarter FY 2010 Financial Results 8Martek Announces Third Quarter FY 2010 Financial Results 9Martek Announces Third Quarter FY 2010 Financial Results 10Martek Announces Third Quarter FY 2010 Financial Results 11Martek Announces Third Quarter FY 2010 Financial Results 12Martek Announces Third Quarter FY 2010 Financial Results 13Martek Announces Third Quarter FY 2010 Financial Results 14
(Date:4/20/2014)... analysis growing in importance for both basic researchers ... and the University of Maryland have developed a ... of gene activity from RNA sequencing (RNA-seq) data., ... famously speedy fish, estimates of gene expression that ... a few minutes, with accuracy that equals or ...
(Date:4/20/2014)... a gift of germsgerms that help to kick-start ... fend off infection, may paradoxically interrupt a newborn,s ... susceptible to dangerous pathogens. , A new ... Hospital of Philadelphia (CHOP) sheds light on immunology ... a crucial role in fostering the rapid production ...
(Date:4/20/2014)... 20, 2014 -- Using corn crop residue to make ... generate more greenhouse gases than gasoline, according to a ... Change . , The findings by a University of ... residue can be used to meet federal mandates to ... , Corn stover -- the stalks, leaves and cobs ...
Breaking Biology News(10 mins):Computational method dramatically speeds up estimates of gene expression 2Study of gut microbes, antibiotics: Clues to improving immunity in premature infants 2Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3
... the first broad-spectrum drugs to combat human rhinoviruses (HRVs), ... on these potential drugs for infections that include the ... Chemistry Letters . Angus MacLeod and colleagues ... they can lead to dangerous complications for millions of ...
... research from the University of Guelph, published Tuesday in ... allowing industrial extraction in a northern Ontario old-growth red ... would significantly threaten biodiversity in Canada. The ... "scientifically irreplaceable system." "Wolf Lake Forest deserves intensive ...
... atmospheric circulation in the southern Australian-New Zealand region has ... the Nature journal Scientific Reports , ... pushed further into the Southern Ocean by rising global ... frequent occurrences of strong El Nios in recent decades, ...
Cached Biology News:New research: Wolf Lake ancient forest is endangered ecosystem 2New research: Wolf Lake ancient forest is endangered ecosystem 3Climate tug of war disrupting Australian atmospheric circulation patterns 2
... 301 Power Supply, 1. 300 V, ... or constant current modes.Single-unit increments in ... reproducibility.Suitable for submarine, mini vertical, and ... as semidry and mini tank blotting ...
Mouse monoclonal [PRMT5-21] to PRMT5 ( Abpromise for all tested applications). entrezGeneID: 10419 SwissProtID: O14744...
B3-1...
Mouse TrkC Affinity Purified Polyclonal Ab...
Biology Products: